#oncology

Eli Lilly’s agreement to acquire CrossBridge Bio for up to $300 million highlights continued appetite for targeted oncology assets, even at the small-company end of biotech dealmaking.

A Northwestern-developed drug reportedly doubled one-year survival in a pancreatic cancer trial, a notable signal in one of oncology’s most difficult treatment areas.

A randomized clinical trial found that men with localized, intermediate-risk prostate cancer recovered faster and saw less short-term disruption to daily life when treated with a minimally invasive approach.

Cancer rates in Canada are projected to remain high in 2026, with 254,100 cases expected and lung, breast, prostate, and colorectal cancers accounting for nearly half of new diagnoses.

Oricell Therapeutics has added another $40 million to what it describes as a pre-IPO financing, taking total funds raised past $110 million. The company is focused on CAR-T therapies for solid tumors.

Roche is expanding work with longtime partner C4 Therapeutics in a deal worth $20 million upfront, underscoring rising interest in degrader-antibody conjugates as a new twist on an already hot cancer-drug category.

A Phase I result highlighted by Medical Xpress points to a transplant regimen that may reduce both relapse risk and severe graft-versus-host disease after donor stem cell transplantation.

A Nature Medicine review traces the rapid advance of personalized mRNA cancer vaccines from experimental concept to active clinical development, marking a turning point for cancer immunotherapy.

New research finds that monthly telehealth nurse check-ins significantly improve treatment adherence among breast cancer patients on oral therapy, reducing the dropout rate by 17 percentage points.

A new mouse study finds that anthocyanin compounds in dark sweet cherries may slow the growth of triple-negative breast cancer, one of the most aggressive and hardest-to-treat forms of the disease.

Three landmark clinical trials confirm that fecal microbiota transplantation can significantly enhance the effectiveness of immunotherapy in advanced solid tumors.

A mysterious RNA molecule found in breast cancer tissue has led researchers to uncover approximately 260,000 cancer-specific small RNAs across 32 tumor types. These orphan non-coding RNAs act as molecular barcodes for cancer identity and could transform how doctors detect and monitor the disease.